SG11201700364PA - Novel glp-1 receptor modulators - Google Patents

Novel glp-1 receptor modulators

Info

Publication number
SG11201700364PA
SG11201700364PA SG11201700364PA SG11201700364PA SG11201700364PA SG 11201700364P A SG11201700364P A SG 11201700364PA SG 11201700364P A SG11201700364P A SG 11201700364PA SG 11201700364P A SG11201700364P A SG 11201700364PA SG 11201700364P A SG11201700364P A SG 11201700364PA
Authority
SG
Singapore
Prior art keywords
receptor modulators
novel glp
glp
novel
modulators
Prior art date
Application number
SG11201700364PA
Other languages
English (en)
Inventor
Marcus F Boehm
Esther Martinborough
Manisha Moorjani
Junko Tamiya
Liming Huang
Adam R Yeager
Enugurthi Brahmachary
Thomas Fowler
Andrew Novak
Premji Meghani
Michael Knaggs
Original Assignee
Celgene Internat Ii Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Internat Ii Sarl filed Critical Celgene Internat Ii Sarl
Publication of SG11201700364PA publication Critical patent/SG11201700364PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201700364PA 2014-07-25 2015-07-24 Novel glp-1 receptor modulators SG11201700364PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462028962P 2014-07-25 2014-07-25
US201462090040P 2014-12-10 2014-12-10
US201562161650P 2015-05-14 2015-05-14
PCT/US2015/042114 WO2016015014A1 (en) 2014-07-25 2015-07-24 Novel glp-1 receptor modulators

Publications (1)

Publication Number Publication Date
SG11201700364PA true SG11201700364PA (en) 2017-02-27

Family

ID=53777037

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201700364PA SG11201700364PA (en) 2014-07-25 2015-07-24 Novel glp-1 receptor modulators

Country Status (14)

Country Link
US (2) US9474755B2 (ja)
EP (1) EP3172199B1 (ja)
JP (2) JP6556237B2 (ja)
KR (1) KR102564946B1 (ja)
CN (2) CN107074820B (ja)
AU (1) AU2015292356B2 (ja)
CA (1) CA2955836C (ja)
EA (1) EA032525B1 (ja)
ES (1) ES2819534T3 (ja)
IL (1) IL249896B (ja)
MX (1) MX2017000972A (ja)
SG (1) SG11201700364PA (ja)
WO (1) WO2016015014A1 (ja)
ZA (1) ZA201700342B (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9278910B2 (en) 2011-05-31 2016-03-08 Receptos, Inc. GLP-1 receptor stabilizers and modulators
WO2014201172A1 (en) 2013-06-11 2014-12-18 Receptos, Inc. Novel glp-1 receptor modulators
KR102564946B1 (ko) * 2014-07-25 2023-08-08 리셉토스 엘엘씨 신규 glp-1 수용체 조절제
WO2016094729A1 (en) * 2014-12-10 2016-06-16 Celgene International Ii Sarl Glp-1 receptor modulators
HUE056805T2 (hu) 2016-09-30 2022-03-28 Receptos Llc GLP-1 receptor modulátor dimetilaminoetanol sója
US11530205B2 (en) * 2017-04-28 2022-12-20 Receptos Llc GLP-1 receptor modulators
US20220193080A1 (en) * 2019-04-11 2022-06-23 University Of The Sciences Allosteric agonists and positive allosteric modulators of glucagon-like peptide 1 receptor
CN112121152B (zh) * 2020-09-25 2021-06-22 南京大学 利司那肽在制备抗肿瘤药物中的应用
CN112898133B (zh) * 2021-01-27 2022-11-15 河北迈尔斯通电子材料有限公司 一种反式酮类中间体的制备方法
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1062206B (it) 1974-02-01 1983-09-20 Rotta Research Lab S P A A S Derivati della tirosina attivi sulla muscolatura liscia
DE2423536A1 (de) 1974-05-15 1975-11-27 Bayer Ag 3-amino-phenylessigsaeure-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
WO1998030231A1 (en) 1997-01-07 1998-07-16 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
KR20010022405A (ko) * 1997-07-31 2001-03-15 진 엠. 듀발 Ｖｌａ-4에 의해 매개된 백혈구 유착을 억제하는설포닐화된 디펩타이드 화합물
US6583139B1 (en) * 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
HU229362B1 (en) 1997-08-22 2013-11-28 Hoffmann La Roche N-alkanoylphenylalanine derivatives
US6191171B1 (en) 1997-11-20 2001-02-20 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
HUP0104579A3 (en) 1998-12-07 2002-05-28 Univ Tulane Glp-1 analogues, pharmaceutical compositions comprising thereof and their use
NZ512663A (en) 1999-01-14 2004-05-28 Amylin Pharmaceuticals Inc Novel exendin agonist formulations and methods of administration thereof
JP2003525931A (ja) 2000-03-07 2003-09-02 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換された３−フェニル−５−アルコキシ−１，３，４−オキサジアゾール−２−オンおよびホルモン感受性リパーゼを阻害するためのその使用
AU2002350217A1 (en) 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
AU2003211560A1 (en) 2002-02-20 2003-09-09 Ajinomoto Co., Inc. Novel phenylalanine derivative
EP2803667A1 (en) 2003-12-22 2014-11-19 Ajinomoto Co., Inc. Phenylalanine derivatives
CA2555594A1 (en) 2004-02-10 2005-08-25 Janssen Pharmaceutica N.V. Pyridazinones as antagonists of a4 integrins
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
WO2008112938A2 (en) 2007-03-13 2008-09-18 New England Medical Center Hospitals, Inc. Composition and method for the treatment of diseases affected by a peptide receptor
CN101679365A (zh) 2007-06-08 2010-03-24 艾德维纳斯医疗私人有限公司 作为葡萄糖激酶激活剂的新型吡咯-2-甲酰胺衍生物、它们的制造方法和药学应用
NZ587343A (en) * 2008-03-07 2012-05-25 Transtech Pharma Inc Oxadiazoanthracene compounds for the treatment of diabetes
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
CN102946882B (zh) * 2010-02-02 2016-05-18 格斯有限公司 苯基丙氨酸衍生物及其作为非肽glp-1受体调节剂的用途
US8501982B2 (en) 2010-06-09 2013-08-06 Receptos, Inc. GLP-1 receptor stabilizers and modulators
TWI523844B (zh) * 2011-01-26 2016-03-01 賽諾菲公司 經胺基取代之３－雜芳醯基胺基－丙酸衍生物及其作為藥物之用途
US9278910B2 (en) 2011-05-31 2016-03-08 Receptos, Inc. GLP-1 receptor stabilizers and modulators
RU2634896C2 (ru) 2011-12-12 2017-11-08 Селджин Интернэшнл Ii Сарл Новые модуляторы рецептора glp-1
WO2014201172A1 (en) 2013-06-11 2014-12-18 Receptos, Inc. Novel glp-1 receptor modulators
KR102564946B1 (ko) * 2014-07-25 2023-08-08 리셉토스 엘엘씨 신규 glp-1 수용체 조절제

Also Published As

Publication number Publication date
MX2017000972A (es) 2017-07-27
JP2017526734A (ja) 2017-09-14
EA032525B1 (ru) 2019-06-28
EP3172199A1 (en) 2017-05-31
WO2016015014A1 (en) 2016-01-28
JP2019142984A (ja) 2019-08-29
IL249896B (en) 2021-02-28
JP6556237B2 (ja) 2019-08-07
ZA201700342B (en) 2018-12-19
US20160038487A1 (en) 2016-02-11
US9839664B2 (en) 2017-12-12
EP3172199B1 (en) 2020-07-01
CN107074820A (zh) 2017-08-18
ES2819534T3 (es) 2021-04-16
AU2015292356B2 (en) 2020-02-06
KR20170040233A (ko) 2017-04-12
CA2955836A1 (en) 2016-01-28
CA2955836C (en) 2023-02-14
CN107074820B (zh) 2021-05-18
IL249896A0 (en) 2017-03-30
US9474755B2 (en) 2016-10-25
KR102564946B1 (ko) 2023-08-08
US20170216392A1 (en) 2017-08-03
CN112457301A (zh) 2021-03-09
EA201790254A1 (ru) 2017-07-31
AU2015292356A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
ZA201605712B (en) Therapeutic combinations with estrogen receptor modulators
IL252257A0 (en) Insulin receptor partial agonists
ZA201700342B (en) Novel glp-1 receptor modulators
GB201514875D0 (en) Receptor
HK1252163A1 (zh) 受體
IL274537A (en) nuclear receptor modulators
HK1222176A1 (zh) 新型 受體調節劑
EP3180332A4 (en) Difluoropyrrolidines as orexin receptor modulators
SG11201704080YA (en) Optical modulator
ZA201605332B (en) Trpa1 modulators
PL3303291T3 (pl) Modulatory ROR-gamma
EP3215893C0 (en) ELECTRO-OPTICAL TILE
PL3303293T3 (pl) Modulatory ROR-gamma
PL3303290T3 (pl) Modulatory ROR-gamma
HRP20190024T1 (hr) Derivati hidroksialkil-piperazina kao modulatori receptora cxcr3
EP3224261A4 (en) Opioid receptor modulators
GB2541589B (en) Image modification
PL3319942T3 (pl) MODULATORY ROR-GAMMA (RORγ)
GB201413262D0 (en) Optical Apparatus
IL252565A0 (en) New receptor modulators
GB201404101D0 (en) Image modification
GB201512714D0 (en) Receptor modulator compounds
GB2529195B (en) Optical apparatus
GB201400215D0 (en) Modulators
GB201405403D0 (en) Receptor modulation